New drug cocktail targets hard-to-treat breast cancer

NCT ID NCT04759248

Ongoing Disease control Sponsor: SOLTI Breast Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whose tumors are estrogen receptor negative or have a non-luminal genetic profile, which may be more responsive to immunotherapy. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab, trastuzumab, and vinorelbine
What this could lead to: If successful, this combination could offer a new treatment option for people with HER2-positive advanced breast cancer that has not responded to standard therapies.
What could go wrong: This is a small phase 2 trial with only 55 participants, so results may not apply to everyone. The drugs can cause side effects like immune reactions, nerve damage, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Complejo Hospitalario Universitario A Coruña (CHUAC)

A Coruña, La Coruña, 15006, Spain
H. Clínico San Cecilio de Granada

Granada, Andalusia, Spain
Hospital Clinic de Barcelona

Barcelona, Spain
Hospital Clinico Universitario de Valencia

Valencia, Spain
Hospital General Universitario de Alicante

Alicante, Spain
Hospital San Pedro de Alcántara

Cáceres, Spain
Hospital Son Espases

Palma de Mallorca, Spain
Hospital Universitari Sant Joan de Reus

Reus, 43201, Spain
Hospital Universitari Vall d' Hebron

Barcelona, Spain
Hospital Universitario 12 de octubre

Madrid, Spain
Hospital Universitario Virgen del Rocio

Seville, Spain
Hospital Universitario de Canarias

Santa Cruz de Tenerife, Canary Islands, 38320, Spain
Hospital de León

León, 24071, Spain
Hospital del Mar

Barcelona, Barcelona, 08003, Spain
Institut Català d'Oncologia Hospitalet

L'Hospitalet de Llobregat, Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.